News | February 04, 2025
Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
Subscribe To Our Newsletter & Stay Updated
